Abiopharma

🔍 Yanai Shlomo (Director)

Company: Amneal Pharmaceuticals, Inc. (AMRX)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Acquired 34,819 shares of Class A Common Stock (Direct)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 320,804.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 34,819 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 19,824 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-06 | Code: A | equity_swap_involved: 0 | shares_owned_after: 19,824.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F2: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.
• F3: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.